Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

51 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Improvement in lipid profiles in antiretroviral-experienced HIV-positive patients with hyperlipidemia after a switch to unboosted atazanavir.
Sension M, Andrade Neto JL, Grinsztejn B, Molina JM, Zavala I, González-García J, Donnelly A, Phiri P, Ledesma E, McGrath D; 067 Study Group. Sension M, et al. J Acquir Immune Defic Syndr. 2009 Jun 1;51(2):153-62. doi: 10.1097/QAI.0b013e3181a5701c. J Acquir Immune Defic Syndr. 2009. PMID: 19346966 Clinical Trial.
Once-daily versus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naive adults with HIV infection: a randomized equivalence trial.
DeJesus E, McCarty D, Farthing CF, Shortino DD, Grinsztejn B, Thomas DA, Schrader SR, Castillo SA, Sension MG, Gough K, Madison SJ; EPV20001 International Study Team. DeJesus E, et al. Clin Infect Dis. 2004 Aug 1;39(3):411-8. doi: 10.1086/422143. Epub 2004 Jul 15. Clin Infect Dis. 2004. PMID: 15307010 Clinical Trial.
Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir.
Wood R, Phanuphak P, Cahn P, Pokrovskiy V, Rozenbaum W, Pantaleo G, Sension M, Murphy R, Mancini M, Kelleher T, Giordano M. Wood R, et al. Among authors: sension m. J Acquir Immune Defic Syndr. 2004 Jun 1;36(2):684-92. doi: 10.1097/00126334-200406010-00005. J Acquir Immune Defic Syndr. 2004. PMID: 15167287 Clinical Trial.
Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV.
Squires K, Lazzarin A, Gatell JM, Powderly WG, Pokrovskiy V, Delfraissy JF, Jemsek J, Rivero A, Rozenbaum W, Schrader S, Sension M, Vibhagool A, Thiry A, Giordano M. Squires K, et al. Among authors: sension m. J Acquir Immune Defic Syndr. 2004 Aug 15;36(5):1011-9. doi: 10.1097/00126334-200408150-00003. J Acquir Immune Defic Syndr. 2004. PMID: 15247553 Clinical Trial.
Efficacy, safety, and tolerability of etravirine with and without darunavir/ritonavir or raltegravir in treatment-experienced patients: analysis of the etravirine early access program in the United States.
Towner W, Lalezari J, Sension MG, Wohlfeiler M, Gathe J, Appelbaum JS, Bellman P, Gottlieb MS, Ryan R, Nijs S, Hoogstoel A, Van Solingen-Ristea R, Witek J. Towner W, et al. Among authors: sension mg. J Acquir Immune Defic Syndr. 2010 Apr;53(5):614-8. doi: 10.1097/QAI.0b013e3181cdebb1. J Acquir Immune Defic Syndr. 2010. PMID: 20134329 Clinical Trial.
51 results